DEVELOPMENT OF MASKED THERAPEUTIC ANTIBODIES TO LIMIT OFF-TARGET EFFECTS: APPLICATION TO ANTI-EGFR ANTIBODIES
First Claim
1. A masked monoclonal antibody (mAb), encoded by a nucleic acid sequence or an amino acid sequence molecule comprising:
- (a) a signal sequence;
(b) a masking epitope sequence;
(c) a linker sequence that is cleavable by a protease specific to a target tissue; and
(d) an antibody or a functional fragment thereof.
0 Assignments
0 Petitions
Accused Products
Abstract
In one embodiment, a masked monoclonal antibody (mAb) is provided, the mAb, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof. In another embodiment, a cross-masked mAb heterodimer complex is provided, comprising a first masked mAb, comprising a first signal sequence, a first masking epitope sequence, a first linker that is cleavable by a protease specific to a target tissue, and a first antibody or fragment thereof; and a second masked mAb, comprising a second signal sequence, a second masking epitope sequence, a second linker that is cleavable by a protease specific to a target tissue, and a second antibody or fragment thereof.
43 Citations
20 Claims
-
1. A masked monoclonal antibody (mAb), encoded by a nucleic acid sequence or an amino acid sequence molecule comprising:
-
(a) a signal sequence; (b) a masking epitope sequence; (c) a linker sequence that is cleavable by a protease specific to a target tissue; and (d) an antibody or a functional fragment thereof. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11)
-
-
12. A cross-masked monoclonal antibody (mAb) heterodimer complex, comprising:
-
a first masked mAb, comprising a first signal sequence, a first masking epitope sequence, a first linker that is cleavable by a protease specific to a target tissue, and a first antibody or fragment thereof; and a second masked mAb, comprising a second signal sequence, a second masking epitope sequence, a second linker that is cleavable by a protease specific to a target tissue, and a second antibody or fragment thereof. - View Dependent Claims (13, 14, 15, 16, 17, 18, 19)
-
-
20. A cross-masked monoclonal antibody (mAb) heterodimer complex, comprising:
a first masked mAb encoded by a nucleic acid sequence of an amino acid sequence of SEQ ID NO;
1 or SEQ ID NO;
5, respectively, and a second masked mAb encoded by a nucleic acid sequence of an amino acid sequence of SEQ ID NO;
2 or SEQ ID NO;
6, respectively.
Specification